ub-621
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02346760)
Timeline
Indications
Mechanism of action
- HSV-2INHIBITOR
HSV-2 inhibitor
Herpes simplex virus (type 1 / strain F) inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ub-621
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04979975 | Phase 2 | Dec 31, 2022 | UBP Greater China (Shanghai) Co., Ltd |
| NCT04714060 | Phase 2 | Oct 1, 2021 | UBP Greater China (Shanghai) Co., Ltd |
| NCT03595995 | Phase 2 | Feb 1, 2019 | United BioPharma |
| NCT02346760 | Phase 1 | Dec 1, 2015 | Taipei Veteran General hospital, United BioPharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UBP Greater China (Shanghai) Co., Ltd | For profit | 2 | 2 | 1 | 2021 |
| United BioPharma | For profit | 2 | 2 | 2 | 2015 |
| Taipei Veteran General hospital | Government | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1